News

electronic stents, bioresorbable electronic stent, BES

With the recent innovation of flexible microelectronic sensor circuits that can be made from bioresorbable materials, it is now possible to create “electronic stents” to monitor a treated lesion...

OrbusNeich, Combo, EPC, HARMONEE study, U.S.

OrbusNeich has announced that the first U.S. patient has been enrolled in the HARMONEE (Harmonized Assessment by Randomized, Multi-center Study of OrbusNEich's COMBO StEnt) stent study. The study...

Shockwave Medical, Lithoplasty, $40 million, funding, Sofinnova, Venrock

Shockwave Medical announced $40 million in funding, co-led by returning investor Sofinnova Partners and new investor Venrock. Also participating were RA Capital, Deerfield, Sectoral Asset...

Boston Scientific, Lotus, PVL, RESPOND, REPRISE II, EuroPCR 2015

A new study evaluating the Boston Scientific Lotus Valve System demonstrated an extremely low rate of paravalvular aortic regurgitation (leakage) for a transcatheter aortic replacement valve....

ART, PBS, pure bioresorbable scaffold, CE Mark

Privately-held company Arterial Remodeling Technologies (ART) announced CE Mark clearance for its next-generation drug-free, pure bioresorbable scaffold used to treat coronary artery disease. The...

St. Jude Medical, OCT, PCI, ILUMIEN, EuroPCR 2015

St. Jude Medical Inc. announced preliminary results from the ILUMIEN I trial and final results from the ILUMIEN II clinical study. Taken together, the findings from both studies show that with...

Visipaque, IOCM, LOCM, angioplasty, EuroPCR 2015

Significantly fewer renal and cardiac events are associated with angioplasty procedures using isosmolar contrast medium (IOCM) agent Visipaque (iodixanol) than those using low-osmolar contrast...

Boston Scientific, Synergy, EVOLVE I, EVOLVE II, EuroPCR 2015, results

Boston Scientific reported positive, long-term data from the EVOLVE Trial of the Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system, with no new major adverse...

IN.PACT Admiral, Global Study, DEB SFA-LONG, long peripheral lesions, EuroPCR

New clinical data from two different studies show the IN.PACT Admiral drug-coated balloon from Medtronic plc successfully treated long lesions in the superficial femoral and popliteal arteries....

St. Jude Medical, FFR, cFFR, CONTRAST, DEFER, study, EuroPCR 2015

St. Jude Medical Inc. announced new results from two clinical studies further supporting the use of its fractional flow reserve (FFR) technology to optimize percutaneous coronary intervention...

CT-FFR, Heartflow Analysis, coronary artery disease, EuroPCR, RIPCORD

Adding the HeartFlow FFRCT Analysis to a standard coronary computed tomography angiogram (cCTA) may change the course of treatment in more than one-third of patients with...

Shimadzu, Trinias, first West Coast installation, Kalispell

Shimadzu Medical Systems USA announced the first U.S. West Coast installation of its Trinias C-12 high performance “crossover” system at Kalispell Regional Medical Center in Kalispell, Montana....

Edwards, Fortis, transcatheter mitral valve, trial, halts enrollment

Edwards Lifesciences announced it has temporarily halted its clinical trial of the Fortis mitral transcatheter heart valve. The company said that in consultation with trial investigators, it was...

Abbott, Absorb, dissolving stent, resorbable, CE Mark, Europe

Abbott announced that it has received CE Mark for the latest advancement of its Absorb stent system, called Absorb GT1. Absorb GT1 combines a fully dissolving stent with a next-generation delivery...

antiplatelet medication, prasugrel, clopidogrel, risk algorithm, SCAI

A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients who stand to benefit from intensive...

cilostazol, DAPT, bridge therapy, surgery, bleeding risk, SCAI

Patients with a high-risk paclitaxel drug-eluting stent given the shorter-acting antiplatelet drug cilostazol prior to a surgical procedure safely transitioned off of dual antiplatelet therapy (...

PROMETHEUS, prasugrel, clopidogrel, heart disease, bleeding, SCAI

Prasugrel (Effient) is more likely to be given to lower-risk heart disease patients undergoing percutaneous coronary intervention (PCI) compared to clopidogrel, according to a new study. Results...

A new study reports that antiplatelet drug ticagrelor (Brilinta) works faster and is more effective in blocking platelet activity in low-risk patients with acute coronary syndrome (ACS) than...

Cath lab

Most community hospitals with cardiac catheterization labs share these facilities with multiple, non-interventional cardiology users, which can be challenging to manage various specialties’ needs...

ACE, accreditation, cath lab, PCI, SCAI 2015, case studies

For the first time, cardiac catheterization laboratory stakeholders now have quality metrics that confirm the value of Accreditation for Cardiovascular Excellence (ACE) accreditation. Three...